573 related articles for article (PubMed ID: 32655584)
1. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
Konwarh R
Front Immunol; 2020; 11():1531. PubMed ID: 32655584
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 immunogenicity at the crossroads.
Karamloo F; König R
Allergy; 2020 Jul; 75(7):1822-1824. PubMed ID: 32401346
[No Abstract] [Full Text] [Related]
3. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
[TBL] [Abstract][Full Text] [Related]
5. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
[TBL] [Abstract][Full Text] [Related]
6. Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.
Zhang BZ; Hu YF; Chen LL; Yau T; Tong YG; Hu JC; Cai JP; Chan KH; Dou Y; Deng J; Wang XL; Hung IF; To KK; Yuen KY; Huang JD
Cell Res; 2020 Aug; 30(8):702-704. PubMed ID: 32612199
[No Abstract] [Full Text] [Related]
7. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
8. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
9. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
Custódio TF; Das H; Sheward DJ; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer MA; Gruzinov AY; Jeffries CM; Graewert MA; Svergun DI; Dobrev N; Remans K; Seeger MA; McInerney GM; Murrell B; Hällberg BM; Löw C
Nat Commun; 2020 Nov; 11(1):5588. PubMed ID: 33149112
[TBL] [Abstract][Full Text] [Related]
10. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
11. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
Palatnik-de-Sousa CB
Front Immunol; 2020; 11():2173. PubMed ID: 32983183
[No Abstract] [Full Text] [Related]
12. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
14. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
16. A human monoclonal antibody blocking SARS-CoV-2 infection.
Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ
Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817
[TBL] [Abstract][Full Text] [Related]
17. Potently neutralizing and protective human antibodies against SARS-CoV-2.
Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
[TBL] [Abstract][Full Text] [Related]
18. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
19. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.
Calina D; Sarkar C; Arsene AL; Salehi B; Docea AO; Mondal M; Islam MT; Zali A; Sharifi-Rad J
Immunol Res; 2020 Dec; 68(6):315-324. PubMed ID: 33006053
[TBL] [Abstract][Full Text] [Related]
20. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
Yi C; Yi Y; Li J
Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
